drugset / Trial / NCT07310784
A Phase II Trial of LM103 in Advanced Melanoma
RandomizedParallel-groupOpen-labelTreatment
Summary
A total of 92 subjects with advanced melanoma who met the inclusion criteria will be randomly assigned in a 1:1 ratio to the experimental group and the control group in this phase II trial. The study will be followed up until 24 months after treatment.
Timeline
- Start
- 2025-12-16
- Primary completion
- 2027-12-31
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Carboplatin | Small molecule | — | — |
| Comparator | Cisplatin | Other / unclassified | — | — |
| Comparator | Dacarbazine | Small molecule | — | — |
| Subject | LM103 TILs | Cell therapy | — | Other |
| Comparator | Paclitaxel | Small molecule | — | — |
| Comparator | Temozolomide | Small molecule | — | — |